Mylod%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520at

# Mylot%20at ## Overview Mylot%20at is a brand name for a medication containing **flutamide**. Flutamide is a non-steroidal anti-androgen used primarily in the management of prostate cancer. It works by blocking the action of androgens, such as testosterone, which can stimulate the growth of prostate cancer cells. ## Primary Indications * **Prostate Cancer:** Typically used in combination with a gonadotropin-releasing hormone (GnRH) analog (e.g., leuprolide, goserelin) or following orchiectomy for the treatment of metastatic prostate cancer. It is often used as part of an initial combination therapy to prevent or treat clinical and biochemical supersaturation due to the initial flare of testosterone from GnRH analogs. ## Adult Dosing * **Prostate Cancer:** The standard dose is **250 mg orally every 8 hours (three times daily)**. This equates to a total daily dose of 750 mg. ## Pediatric Dosing * There is **no established pediatric use** for Mylot%20at (flutamide). Its use is generally limited to adult patients. ## Dose Adjustments * **Hepatic Impairment:** Caution is advised in patients with hepatic impairment. Dosage adjustments are not specifically defined, but liver function should be closely monitored. If signs of liver toxicity occur, the drug should be discontinued. * **Renal Impairment:** No specific dose adjustments are typically recommended for renal impairment, but clinical judgment should be exercised. ## Contraindications * **Hypersensitivity:** Known hypersensitivity to flutamide or any of its components. * **Hepatic Impairment:** Generally contraindicated in patients with clinically significant hepatic impairment. * **Pregnancy and Lactation:** Flutamide is contraindicated in women who are or may become pregnant and in breastfeeding women due to potential harm to the fetus or infant. ## Adverse Effects * **Common:** Hot flashes, decreased libido, erectile dysfunction, gynecomastia, nausea, vomiting, diarrhea, anorexia, fatigue, dizziness. * **Serious:** * **Hepatotoxicity:** Can be severe and potentially fatal. Symptoms include jaundice, dark urine, abdominal pain, elevated liver enzymes (ALT, AST). * **Pulmonary Toxicity:** Interstitial pneumonitis, fibrosis. * **Hematologic Effects:** Anemia, leukopenia, thrombocytopenia. * **Thromboembolic Events:** Although rare, can occur. * **Methemoglobinemia:** Rare but serious. ## Key Drug Interactions * **Theophylline:** Flutamide may inhibit the metabolism of theophylline, potentially leading to increased theophylline levels and toxicity. Monitor theophylline levels and adjust dose if necessary. * **Warfarin:** Cases of increased INR and bleeding have been reported when flutamide is used with warfarin. Close monitoring of INR is recommended, especially when initiating or discontinuing flutamide. Dose adjustments of warfarin may be needed. * **Cytochrome P450 Substrates:** Flutamide may inhibit CYP1A2 and potentially other CYP enzymes. Use with caution and consider monitoring for increased effects or toxicity of other medications metabolized by these enzymes. ## Monitoring * **Liver Function Tests (LFTs):** Baseline and regular monitoring of ALT, AST, bilirubin, and alkaline phosphatase is crucial, especially during the first few months of therapy and periodically thereafter. Discontinue flutamide immediately if signs of liver injury appear. * **Prostate-Specific Antigen (PSA):** Monitor PSA levels as indicated for prostate cancer management. * **Complete Blood Count (CBC):** Periodic monitoring for anemia, leukopenia, and thrombocytopenia. * **Signs and Symptoms of Pulmonary Toxicity:** Patients should be advised to report any new or worsening respiratory symptoms. ## Clinical Pearls * Mylot%20at (flutamide) should **always be used in combination** with a GnRH analog or after orchiectomy to achieve a complete androgen blockade. Monotherapy with flutamide is generally not recommended for prostate cancer. * Hepatotoxicity is a significant risk. Patients and caregivers should be educated on the signs and symptoms of liver dysfunction and instructed to seek immediate medical attention if they occur. * Women of childbearing potential should avoid exposure to flutamide. --- **Disclaimer:** This information is intended for healthcare professionals and is a summary of essential drug information. It is not exhaustive and does not replace professional medical judgment. Always consult the most current prescribing information (package insert) and relevant guidelines for complete details, including specific indications, contraindications, warnings, precautions, adverse reactions, and drug interactions, before making any treatment decisions. Dosing may vary based on individual patient factors and local protocols.